Two Cases of Fatal Encephalopathy Related to Ifosfamide: An Adverse Role of Aprepitant

• Main Authors: Alice Séjourné, Sabine Noal, Mathieu Boone, Céline Bihan, Marion Sassier, Michel Andrejak, Bruno Chauffert
• Format: Article
• Language: English
• Published: Karger Publishers 2014-09-01
• Series: Case Reports in Oncology
• Subjects: Aprepitant; Ifosfamide; Encephalopathy; Drug interaction
• Online Access: http://www.karger.com/Article/FullText/368184

Ifosfamide is used in the treatment of sarcomas and other tumors. It sometimes provokes encephalopathy, which is a serious complication even if it is usually reversible within 48-72 h after drug cessation. Ifosfamide is required to be activated by hepatic cytochrome P450 (CYP), especially the 3A4 subtype, leading to 4-hydroxy-ifosfamide. Ifosfamide is also converted by CYP3A4 to inactive but neurotoxic metabolites. Aprepitant is a neurokinin-1 receptor antagonist that is a potent antiemetic used in combination with 5-HT3 antagonists and corticosteroids. Aprepitant has an inhibitory effect, as well as a possible inductive effect, on CYP3A4. Since ifosfamide and aprepitant are both substrates of CYP3A4, a pharmacokinetic interaction could result in secondary effects such as the potentialization of neurological side effects. In this report, we describe 2 cases of fatal encephalopathy in patients who have received both ifosfamide and aprepitant, and we discuss the mechanisms that could be involved. Our observations draw attention to the fact that aprepitant must be avoided, or at least used with caution, in patients who are receiving ifosfamide due to the risk of severe neurological side effects.